RecruitingPhase 1NCT07567781

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

A Phase 1 Study to Evaluate the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of Cocktail Probe Substrates of CYP3A and Select Transporters in Healthy Adult Subjects

Sponsor

AbbVie

Enrollment

12 participants

Start Date

Apr 30, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteers

Summary

The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria2

Laboratory values meet the criteria specified in the protocol.
A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).

Exclusion Criteria4

History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study treatment administration.
Use of tobacco- or nicotine-containing products within 3 months (90 days) prior to the first dose of study treatment.
Participant has prior exposure to ABBV-722 within 90 days prior to the first dose of study treatment.

Interested in this trial?

Get notified about updates and connect with the research team.